Drug that can delay prostate cancer for over a year in terminal patients is approved

The drug could be rolled out in the NHS before the end of the year, Thomas Kingsley reports

Prostate cancer is the most common cancer among men (PA)

A prostate cancer drug for terminal patients that can put the disease on hold for a year has been approved by UK regulators.

The Medicines and Healthcare products Regulatory Agency (MHRA) has ruled in favour of Pluvicto, which could delay the progression of the disease by more than a year.

Cancer experts said it was a “major clinical advance”, giving fresh hope to men with metastatic disease.